Clinical Trials Logo

Mental Disorders clinical trials

View clinical trials related to Mental Disorders.

Filter by:

NCT ID: NCT00248027 Terminated - Clinical trials for Schizophreniform,First Episode Psychosis

Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic

Start date: January 2004
Phase: Phase 1
Study type: Observational

Main Research questions: 1. Who are the patients referred for treatment at the Psychotic Disorders Clinic? 2. What are the outcomes from treatment for first episode psychosis in multiple outcome domains? 3. What hospital resources are used over the early course of the illness? 4. How satisfied are patients and family with the treatment and services they received? This is an important study that will help us evaluate the service and treatment offered by the Psychotic Disorders Clinic's specialized early intervention program,which helps young people experiencing early stages of psychotic illness.A growing body of evidence suggests that intervening earlier in the course of the illness with specialized and complimentary pharmacological and psychosocial treatment may be associated with improved outcomes.

NCT ID: NCT00232349 Terminated - Schizophrenia Clinical Trials

Efficacy of Galantamine to Treat Schizophrenia

Start date: February 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements from baseline to end of study on a measure of quality of life and a measure of independent living skills.

NCT ID: NCT00184405 Terminated - Clinical trials for Psychiatric Disorder NOS

Child Results Following Preventive Children of Parents With Psychiatric and Addictive Problems (COPP) Groups

Start date: March 2005
Phase:
Study type: Observational

This is a study evaluating changes in quality of life and global functioning across and after a manualized peer-group preventive intervention for children of parents with psychiatric or addictive problems.

NCT ID: NCT00183612 Terminated - Bipolar Disorder Clinical Trials

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

Start date: May 2000
Phase: N/A
Study type: Interventional

This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.

NCT ID: NCT00174603 Terminated - Clinical trials for Major Depression With Psychotic Features

Treatment of Depression With Quetiapine

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quetiapine monotherapy would have similar effects to the combination of a first generation antipsychotic plus an antidepressant for the treatment of a major depressive episode with psychosis.

NCT ID: NCT00174590 Terminated - Clinical trials for Major Depression With Psychotic Features

Treatment of Major Depressive Disorder With Psychotic Features.

Start date: September 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features

NCT ID: NCT00169026 Terminated - Schizophrenia Clinical Trials

Alcoholism and Schizophrenia: Effects of Clozapine

Start date: May 1999
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.

NCT ID: NCT00160147 Terminated - Clinical trials for Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.

NCT ID: NCT00049738 Terminated - Schizophrenia Clinical Trials

Screening for Childhood-Onset Psychotic Disorders

Start date: October 29, 2002
Phase: N/A
Study type: Observational

The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. This study will also recruit individuals for various treatment studies. Childhood psychotic disorders are debilitating conditions in which children have auditory or visual hallucinations and disorganized thoughts. This study will examine psychotic disorders in children in an inpatient setting. Participants in this study will be admitted to the NIH Clinical Center for up to 9 weeks under one or more of the following conditions: current medication, no medication, or tapered medication. Participants will undergo blood, urine, metabolic, and intellectual functioning tests. An electrocardiogram (EKG) and electroencephalogram (EEG) will be performed. A magnetic resonance imaging (MRI) scan of the brain will be taken and infrared oculography will be used to measure eye movements. Participants and their family members may also be asked to participate in a study of genetics in children with psychotic illnesses. Children meeting criteria for childhood onset schizophrenia may be offered participation in a medication comparison protocol.

NCT ID: NCT00001198 Terminated - Schizophrenia Clinical Trials

Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia

Start date: March 19, 1984
Phase: N/A
Study type: Observational

A study of children and adolescents (current N=100) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Earlier studies have documented the continuity between COS and adult onset cases (See Jacobsen and Rapoport, 1998 for review). The focus has now shifted to increasing the sample size and evaluation of familial risk factors including: psychiatric diagnoses of family members; smooth pursuit eye movements; neuropsychological tests deficits, and obtaining blood for cell lines for genetic studies (family members only, this is also covered under 96-M-0060, Dr. Ellen Sidransky). A study of obstetrical records of COS probands indicated no increase in adverse pre or perinatal events for these cases compared with obstetrical records of their siblings (Nicolson et al submitted). In contrast, several findings point to increased risk for these probands. To date, a total of 5 (10.4%) COS subjects were found to have previously unknown cytogenetic abnormalities (Microdeletion of 22q11 (3 cases), (Usiskin et al, submitted), Mosaic 45X0 (one case) (Kumra et al, 1998) and balanced 1:7 translocation (Gordon et al 1994). The study of first degree relatives of these very rare cases addresses the hypothesis that risk factors, most probably genetic, are increased in immediate family members relative both to community controls and to the relatives of patients with chronic, treatment resistant, adult-onset schizophrenia (AOS). A second hypothesis is that COS familial risk factors show significant relationship to the developmental delays/abnormalities being observed in the COS probands. As a total of 50 additional COS subjects will be studied over the next 5 years, the pediatric control sample for the probands will also be increased, determined by the need to have concurrent measures for patients and controls to maintain measurement validity. Thus a total of 600 additional subjects are to be studied including 50 controls for COS probands, 150 COS relatives, 150 controls for COS relatives, and 250 relatives of adult onset schizophrenics (AOS).